#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Mechanisms	_
1-2	11-13	of	_
1-3	14-21	Working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
1-4	22-28	Memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
1-5	29-39	Impairment	_
1-6	40-42	in	_
1-7	43-56	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-8	57-67	Background	_
1-9	68-71	The	_
1-10	72-78	neural	_
1-11	79-89	correlates	_
1-12	90-92	of	_
1-13	93-100	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
1-14	101-107	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
1-15	108-109	(	_
1-16	110-112	WM	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-17	113-114	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-18	115-125	impairment	_
1-19	126-128	in	_
1-20	129-142	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-21	143-149	remain	_
1-22	150-151	a	_
1-23	152-155	key	_
1-24	156-162	puzzle	_
1-25	163-165	in	_
1-26	166-179	understanding	_
1-27	180-183	the	_
1-28	184-193	cognitive	_
1-29	194-202	deficits	_
1-30	203-206	and	_
1-31	207-218	dysfunction	_
1-32	219-221	of	_
1-33	222-234	dorsolateral	_
1-34	235-245	prefrontal	_
1-35	246-252	cortex	_
1-36	253-261	observed	_
1-37	262-264	in	_
1-38	265-268	the	_
1-39	269-277	disorder	_
1-40	278-279	.	_

2-1	280-282	We	_
2-2	283-289	sought	_
2-3	290-292	to	_
2-4	293-302	determine	_
2-5	303-310	whether	_
2-6	311-319	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-7	320-324	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-8	325-338	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-9	339-346	exhibit	_
2-10	347-349	an	_
2-11	350-360	alteration	_
2-12	361-363	in	_
2-13	364-367	the	_
2-14	368-378	inverted-U	_
2-15	379-391	relationship	_
2-16	392-399	between	_
2-17	400-402	WM	_
2-18	403-407	load	_
2-19	408-411	and	_
2-20	412-422	activation	_
2-21	423-427	that	_
2-22	428-430	we	_
2-23	431-439	recently	_
2-24	440-448	observed	_
2-25	449-451	in	_
2-26	452-459	healthy	_
2-27	460-471	individuals	_
2-28	472-473	,	_
2-29	474-477	and	_
2-30	478-485	whether	_
2-31	486-490	this	_
2-32	491-496	could	_
2-33	497-504	account	_
2-34	505-508	for	_
2-35	509-511	WM	_
2-36	512-520	deficits	_
2-37	521-523	in	_
2-38	524-528	this	_
2-39	529-539	population	_
2-40	540-541	.	_

3-1	542-549	Methods	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
3-2	550-559	Medicated	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
3-3	560-561	(	_
3-4	562-566	N=30	_
3-5	567-568	)	_
3-6	569-572	and	_
3-7	573-584	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
3-8	585-586	(	_
3-9	587-591	N=21	_
3-10	592-593	)	_
3-11	594-602	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-12	603-607	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-13	608-621	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-14	622-625	and	_
3-15	626-633	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-16	634-642	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-17	643-644	(	_
3-18	645-649	N=45	_
3-19	650-651	)	_
3-20	652-661	performed	_
3-21	662-665	the	_
3-22	666-678	self-ordered	_
3-23	679-681	WM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-24	682-686	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-25	687-693	during	_
3-26	694-704	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-27	705-713	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-28	714-723	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-29	724-731	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-30	732-733	.	_

4-1	734-736	We	_
4-2	737-747	identified	_
4-3	748-755	regions	_
4-4	756-766	exhibiting	_
4-5	767-769	an	_
4-6	770-777	altered	_
4-7	778-781	fit	_
4-8	782-784	to	_
4-9	785-787	an	_
4-10	788-798	inverted-U	_
4-11	799-811	relationship	_
4-12	812-819	between	_
4-13	820-822	WM	_
4-14	823-827	load	_
4-15	828-831	and	_
4-16	832-842	activation	_
4-17	843-847	that	_
4-18	848-852	were	_
4-19	853-857	also	_
4-20	858-868	predictive	_
4-21	869-871	of	_
4-22	872-874	WM	_
4-23	875-886	performance	_
4-24	887-888	.	_

5-1	889-896	Results	_
5-2	897-898	A	_
5-3	899-906	blunted	_
5-4	907-917	inverted-U	_
5-5	918-926	response	_
5-6	927-930	was	_
5-7	931-939	observed	_
5-8	940-942	in	_
5-9	943-947	left	_
5-10	948-953	DLPFC	_
5-11	954-956	in	_
5-12	957-965	patients	_
5-13	966-969	and	_
5-14	970-973	was	_
5-15	974-984	associated	_
5-16	985-989	with	_
5-17	990-1000	behavioral	_
5-18	1001-1009	deficits	_
5-19	1010-1012	in	_
5-20	1013-1015	WM	_
5-21	1016-1024	capacity	_
5-22	1025-1026	.	_

6-1	1027-1029	In	_
6-2	1030-1038	addition	_
6-3	1039-1040	,	_
6-4	1041-1052	suppression	_
6-5	1053-1055	of	_
6-6	1056-1062	medial	_
6-7	1063-1073	prefrontal	_
6-8	1074-1080	cortex	_
6-9	1081-1082	(	_
6-10	1083-1087	mPFC	_
6-11	1088-1089	)	_
6-12	1090-1096	during	_
6-13	1097-1099	WM	_
6-14	1100-1103	was	_
6-15	1104-1111	reduced	_
6-16	1112-1114	in	_
6-17	1115-1123	patients	_
6-18	1124-1125	,	_
6-19	1126-1129	and	_
6-20	1130-1133	was	_
6-21	1134-1138	also	_
6-22	1139-1149	associated	_
6-23	1150-1154	with	_
6-24	1155-1161	poorer	_
6-25	1162-1164	WM	_
6-26	1165-1173	capacity	_
6-27	1174-1176	in	_
6-28	1177-1185	patients	_
6-29	1186-1187	.	_

7-1	1188-1195	Finally	_
7-2	1196-1197	,	_
7-3	1198-1208	activation	_
7-4	1209-1211	of	_
7-5	1212-1218	visual	_
7-6	1219-1225	cortex	_
7-7	1226-1228	in	_
7-8	1229-1232	the	_
7-9	1233-1239	cuneus	_
7-10	1240-1243	was	_
7-11	1244-1252	elevated	_
7-12	1253-1255	in	_
7-13	1256-1264	patients	_
7-14	1265-1268	and	_
7-15	1269-1279	associated	_
7-16	1280-1284	with	_
7-17	1285-1293	improved	_
7-18	1294-1296	WM	_
7-19	1297-1305	capacity	_
7-20	1306-1307	.	_

8-1	1308-1316	Together	_
8-2	1317-1318	,	_
8-3	1319-1324	these	_
8-4	1325-1333	findings	_
8-5	1334-1343	explained	_
8-6	1344-1346	55	_
8-7	1347-1348	%	_
8-8	1349-1351	of	_
8-9	1352-1355	the	_
8-10	1356-1371	interindividual	_
8-11	1372-1380	variance	_
8-12	1381-1383	in	_
8-13	1384-1386	WM	_
8-14	1387-1395	capacity	_
8-15	1396-1400	when	_
8-16	1401-1409	combined	_
8-17	1410-1414	with	_
8-18	1415-1425	diagnostic	_
8-19	1426-1429	and	_
8-20	1430-1440	medication	_
8-21	1441-1447	status	_
8-22	1448-1449	,	_
8-23	1450-1455	which	_
8-24	1456-1461	alone	_
8-25	1462-1471	accounted	_
8-26	1472-1475	for	_
8-27	1476-1480	only	_
8-28	1481-1483	22	_
8-29	1484-1485	%	_
8-30	1486-1488	of	_
8-31	1489-1492	the	_
8-32	1493-1501	variance	_
8-33	1502-1504	in	_
8-34	1505-1507	WM	_
8-35	1508-1516	capacity	_
8-36	1517-1518	.	_

9-1	1519-1530	Conclusions	_
9-2	1531-1536	These	_
9-3	1537-1545	findings	_
9-4	1546-1554	identify	_
9-5	1555-1556	a	_
9-6	1557-1562	novel	_
9-7	1563-1572	biomarker	_
9-8	1573-1576	and	_
9-9	1577-1585	putative	_
9-10	1586-1595	mechanism	_
9-11	1596-1598	of	_
9-12	1599-1601	WM	_
9-13	1602-1610	deficits	_
9-14	1611-1613	in	_
9-15	1614-1622	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-16	1623-1627	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-17	1628-1641	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-18	1642-1643	,	_
9-19	1644-1645	a	_
9-20	1646-1655	reduction	_
9-21	1656-1658	or	_
9-22	1659-1669	flattening	_
9-23	1670-1672	of	_
9-24	1673-1676	the	_
9-25	1677-1687	inverted-U	_
9-26	1688-1700	relationship	_
9-27	1701-1708	between	_
9-28	1709-1719	activation	_
9-29	1720-1723	and	_
9-30	1724-1726	WM	_
9-31	1727-1731	load	_
9-32	1732-1740	observed	_
9-33	1741-1743	in	_
9-34	1744-1751	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-35	1752-1763	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-36	1764-1766	in	_
9-37	1767-1771	left	_
9-38	1772-1784	dorsolateral	_
9-39	1785-1795	prefrontal	_
9-40	1796-1802	cortex	_
9-41	1803-1804	.	_

10-1	1805-1812	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1813-1816	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1817-1826	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1827-1839	Participants	_
10-5	1840-1843	All	_
10-6	1844-1854	procedures	_
10-7	1855-1859	were	_
10-8	1860-1868	approved	_
10-9	1869-1871	by	_
10-10	1872-1875	the	_
10-11	1876-1879	New	_
10-12	1880-1884	York	_
10-13	1885-1890	State	_
10-14	1891-1902	Psychiatric	_
10-15	1903-1912	Institute	_
10-16	1913-1914	(	_
10-17	1915-1920	NYSPI	_
10-18	1921-1922	)	_
10-19	1923-1936	Institutional	_
10-20	1937-1943	Review	_
10-21	1944-1949	Board	_
10-22	1950-1951	.	_

11-1	1952-1964	Participants	_
11-2	1965-1973	provided	_
11-3	1974-1981	written	_
11-4	1982-1990	informed	_
11-5	1991-1998	consent	_
11-6	1999-2000	,	_
11-7	2001-2004	and	_
11-8	2005-2012	patient	_
11-9	2013-2025	participants	_
11-10	2026-2030	were	_
11-11	2031-2037	deemed	_
11-12	2038-2040	to	_
11-13	2041-2045	have	_
11-14	2046-2054	capacity	_
11-15	2055-2057	to	_
11-16	2058-2065	provide	_
11-17	2066-2073	consent	_
11-18	2074-2076	by	_
11-19	2077-2079	an	_
11-20	2080-2091	independent	_
11-21	2092-2104	psychiatrist	_
11-22	2105-2106	.	_

12-1	2107-2115	Patients	_
12-2	2116-2120	were	_
12-3	2121-2132	outpatients	_
12-4	2133-2142	recruited	_
12-5	2143-2147	from	_
12-6	2148-2156	research	_
12-7	2157-2167	facilities	_
12-8	2168-2170	at	_
12-9	2171-2176	NYSPI	_
12-10	2177-2178	,	_
12-11	2179-2182	and	_
12-12	2183-2190	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-13	2191-2203	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-14	2204-2208	were	_
12-15	2209-2218	recruited	_
12-16	2219-2222	via	_
12-17	2223-2237	advertisements	_
12-18	2238-2239	.	_

13-1	2240-2243	The	_
13-2	2244-2249	final	_
13-3	2250-2256	sample	_
13-4	2257-2265	included	_
13-5	2266-2268	21	_
13-6	2269-2280	unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
13-7	2281-2289	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
13-8	2290-2291	,	_
13-9	2292-2294	30	_
13-10	2295-2304	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
13-11	2305-2313	patients	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
13-12	2314-2315	,	_
13-13	2316-2319	and	_
13-14	2320-2322	45	_
13-15	2323-2330	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-16	2331-2338	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-17	2339-2351	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-18	2352-2353	(	_
13-19	2354-2357	see	_
13-20	2358-2368	supplement	_
13-21	2369-2372	for	_
13-22	2373-2380	details	_
13-23	2381-2382	)	_
13-24	2383-2384	.	_

14-1	2385-2394	Inclusion	_
14-2	2395-2403	criteria	_
14-3	2404-2407	for	_
14-4	2408-2416	patients	_
14-5	2417-2421	were	_
14-6	2422-2423	:	_
14-7	2424-2425	(	_
14-8	2426-2427	1	_
14-9	2428-2429	)	_
14-10	2430-2438	lifetime	_
14-11	2439-2445	DSM-IV	_
14-12	2446-2455	diagnosis	_
14-13	2456-2458	of	_
14-14	2459-2472	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-15	2473-2474	,	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-16	2475-2490	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-17	2491-2492	,	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-18	2493-2495	or	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-19	2496-2512	schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-20	2513-2521	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-21	2522-2525	and	_
14-22	2526-2527	(	_
14-23	2528-2529	2	_
14-24	2530-2531	)	_
14-25	2532-2540	negative	_
14-26	2541-2546	urine	_
14-27	2547-2557	toxicology	_
14-28	2558-2559	.	_

15-1	2560-2571	Unmedicated	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
15-2	2572-2580	patients	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
15-3	2581-2585	were	_
15-4	2586-2596	medication	_
15-5	2597-2601	free	_
15-6	2602-2605	for	_
15-7	2606-2608	at	_
15-8	2609-2614	least	_
15-9	2615-2618	two	_
15-10	2619-2624	weeks	_
15-11	2625-2626	,	_
15-12	2627-2632	while	_
15-13	2633-2642	medicated	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
15-14	2643-2651	patients	http://maven.renci.org/NeuroBridge/neurobridge#Medicated
15-15	2652-2656	were	_
15-16	2657-2659	on	_
15-17	2660-2666	stable	_
15-18	2667-2672	doses	_
15-19	2673-2675	of	_
15-20	2676-2687	risperidone	_
15-21	2688-2689	,	_
15-22	2690-2702	aripiprazole	_
15-23	2703-2704	,	_
15-24	2705-2715	lurasidone	_
15-25	2716-2717	,	_
15-26	2718-2730	paliperidone	_
15-27	2731-2732	,	_
15-28	2733-2735	or	_
15-29	2736-2747	haloperidol	_
15-30	2748-2751	for	_
15-31	2752-2754	at	_
15-32	2755-2760	least	_
15-33	2761-2762	4	_
15-34	2763-2768	weeks	_
15-35	2769-2770	,	_
15-36	2771-2775	with	_
15-37	2776-2778	no	_
15-38	2779-2792	antipsychotic	_
15-39	2793-2805	polypharmacy	_
15-40	2806-2809	and	_
15-41	2810-2812	no	_
15-42	2813-2824	psychiatric	_
15-43	2825-2827	ER	_
15-44	2828-2833	visit	_
15-45	2834-2836	or	_
15-46	2837-2852	hospitalization	_
15-47	2853-2856	for	_
15-48	2857-2859	at	_
15-49	2860-2865	least	_
15-50	2866-2867	3	_
15-51	2868-2874	months	_
15-52	2875-2876	.	_

16-1	2877-2886	Inclusion	_
16-2	2887-2895	criteria	_
16-3	2896-2899	for	_
16-4	2900-2907	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-5	2908-2916	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-6	2917-2921	were	_
16-7	2922-2923	:	_
16-8	2924-2925	(	_
16-9	2926-2927	1	_
16-10	2928-2929	)	_
16-11	2930-2932	no	_
16-12	2933-2940	history	_
16-13	2941-2943	of	_
16-14	2944-2950	DSM-IV	_
16-15	2951-2957	Axis-I	_
16-16	2958-2966	disorder	_
16-17	2967-2968	;	_
16-18	2969-2970	(	_
16-19	2971-2972	2	_
16-20	2973-2974	)	_
16-21	2975-2977	no	_
16-22	2978-2984	family	_
16-23	2985-2992	history	_
16-24	2993-2994	(	_
16-25	2995-3007	first-degree	_
16-26	3008-3009	)	_
16-27	3010-3012	of	_
16-28	3013-3022	psychotic	_
16-29	3023-3030	illness	_
16-30	3031-3032	;	_
16-31	3033-3036	and	_
16-32	3037-3038	(	_
16-33	3039-3040	3	_
16-34	3041-3042	)	_
16-35	3043-3051	negative	_
16-36	3052-3057	urine	_
16-37	3058-3068	toxicology	_
16-38	3069-3070	.	_

17-1	3071-3080	Exclusion	_
17-2	3081-3089	criteria	_
17-3	3090-3093	for	_
17-4	3094-3097	all	_
17-5	3098-3104	groups	_
17-6	3105-3113	included	_
17-7	3114-3125	significant	_
17-8	3126-3133	medical	_
17-9	3134-3137	and	_
17-10	3138-3150	neurological	_
17-11	3151-3160	illnesses	_
17-12	3161-3162	,	_
17-13	3163-3170	current	_
17-14	3171-3177	misuse	_
17-15	3178-3180	of	_
17-16	3181-3191	substances	_
17-17	3192-3197	other	_
17-18	3198-3202	than	_
17-19	3203-3211	nicotine	_
17-20	3212-3213	,	_
17-21	3214-3223	pregnancy	_
17-22	3224-3225	,	_
17-23	3226-3229	and	_
17-24	3230-3237	nursing	_
17-25	3238-3239	.	_

18-1	3240-3246	Groups	_
18-2	3247-3251	were	_
18-3	3252-3259	matched	_
18-4	3260-3263	for	_
18-5	3264-3267	age	_
18-6	3268-3269	,	_
18-7	3270-3276	gender	_
18-8	3277-3278	,	_
18-9	3279-3282	and	_
18-10	3283-3291	parental	_
18-11	3292-3305	socioeconomic	_
18-12	3306-3312	status	_
18-13	3313-3314	.	_

19-1	3315-3318	See	_
19-2	3319-3324	Table	_
19-3	3325-3326	1	_
19-4	3327-3330	for	_
19-5	3331-3342	demographic	_
19-6	3343-3346	and	_
19-7	3347-3355	clinical	_
19-8	3356-3360	data	_
19-9	3361-3362	.	_

20-1	3363-3367	Task	_
20-2	3368-3378	Procedures	_
20-3	3379-3383	Task	_
20-4	3384-3394	procedures	_
20-5	3395-3398	are	_
20-6	3399-3407	detailed	_
20-7	3408-3410	in	_
20-8	3411-3414	the	_
20-9	3415-3425	supplement	_
20-10	3426-3427	,	_
20-11	3428-3431	and	_
20-12	3432-3436	have	_
20-13	3437-3441	been	_
20-14	3442-3451	described	_
20-15	3452-3462	previously	_
20-16	3463-3464	.	_

21-1	3465-3472	Briefly	_
21-2	3473-3474	,	_
21-3	3475-3480	eight	_
21-4	3481-3494	line-drawings	_
21-5	3495-3497	of	_
21-6	3498-3520	difficult-to-verbalize	_
21-7	3521-3528	objects	_
21-8	3529-3533	were	_
21-9	3534-3543	presented	_
21-10	3544-3545	,	_
21-11	3546-3549	and	_
21-12	3550-3562	participants	_
21-13	3563-3567	were	_
21-14	3568-3578	instructed	_
21-15	3579-3581	to	_
21-16	3582-3588	select	_
21-17	3589-3593	each	_
21-18	3594-3600	object	_
21-19	3601-3605	once	_
21-20	3606-3607	,	_
21-21	3608-3610	in	_
21-22	3611-3614	any	_
21-23	3615-3620	order	_
21-24	3621-3622	.	_

22-1	3623-3628	After	_
22-2	3629-3633	each	_
22-3	3634-3640	object	_
22-4	3641-3644	was	_
22-5	3645-3653	selected	_
22-6	3654-3655	,	_
22-7	3656-3659	all	_
22-8	3660-3667	objects	_
22-9	3668-3672	were	_
22-10	3673-3688	pseudo-randomly	_
22-11	3689-3699	rearranged	_
22-12	3700-3702	on	_
22-13	3703-3706	the	_
22-14	3707-3713	screen	_
22-15	3714-3715	.	_

23-1	3716-3728	Participants	_
23-2	3729-3733	then	_
23-3	3734-3737	had	_
23-4	3738-3740	to	_
23-5	3741-3747	select	_
23-6	3748-3750	an	_
23-7	3751-3757	object	_
23-8	3758-3761	not	_
23-9	3762-3769	already	_
23-10	3770-3778	selected	_
23-11	3779-3780	,	_
23-12	3781-3783	so	_
23-13	3784-3788	that	_
23-14	3789-3791	at	_
23-15	3792-3796	each	_
23-16	3797-3801	step	_
23-17	3802-3807	there	_
23-18	3808-3811	was	_
23-19	3812-3815	one	_
23-20	3816-3820	more	_
23-21	3821-3840	previously-selected	_
23-22	3841-3847	object	_
23-23	3848-3850	to	_
23-24	3851-3859	remember	_
23-25	3860-3861	.	_

24-1	3862-3863	A	_
24-2	3864-3874	perceptual	_
24-3	3875-3878	and	_
24-4	3879-3884	motor	_
24-5	3885-3892	control	_
24-6	3893-3897	task	_
24-7	3898-3901	was	_
24-8	3902-3906	used	_
24-9	3907-3916	following	_
24-10	3917-3926	identical	_
24-11	3927-3937	procedures	_
24-12	3938-3939	,	_
24-13	3940-3946	except	_
24-14	3947-3951	that	_
24-15	3952-3955	one	_
24-16	3956-3962	object	_
24-17	3963-3966	was	_
24-18	3967-3973	marked	_
24-19	3974-3978	with	_
24-20	3979-3981	an	_
24-21	3982-3990	asterisk	_
24-22	3991-3994	and	_
24-23	3995-4007	participants	_
24-24	4008-4012	were	_
24-25	4013-4023	instructed	_
24-26	4024-4026	to	_
24-27	4027-4033	simply	_
24-28	4034-4040	select	_
24-29	4041-4044	the	_
24-30	4045-4051	marked	_
24-31	4052-4058	object	_
24-32	4059-4060	.	_

25-1	4061-4073	Participants	_
25-2	4074-4078	were	_
25-3	4079-4083	paid	_
25-4	4084-4085	$	_
25-5	4086-4090	0.25	_
25-6	4091-4094	per	_
25-7	4095-4102	correct	_
25-8	4103-4111	response	_
25-9	4112-4115	for	_
25-10	4116-4120	both	_
25-11	4121-4126	tasks	_
25-12	4127-4128	.	_

26-1	4129-4132	Our	_
26-2	4133-4140	primary	_
26-3	4141-4148	measure	_
26-4	4149-4151	of	_
26-5	4152-4163	performance	_
26-6	4164-4167	was	_
26-7	4168-4170	WM	_
26-8	4171-4179	capacity	_
26-9	4180-4181	,	_
26-10	4182-4184	as	_
26-11	4185-4194	estimated	_
26-12	4195-4197	by	_
26-13	4198-4199	a	_
26-14	4200-4218	maximum-likelihood	_
26-15	4219-4224	model	_
26-16	4225-4226	(	_
26-17	4227-4230	see	_
26-18	4231-4241	supplement	_
26-19	4242-4245	and	_
26-20	4246-4247	)	_
26-21	4248-4249	.	_

27-1	4250-4254	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
27-2	4255-4265	Procedures	_
27-3	4266-4270	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-4	4271-4282	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-5	4283-4284	,	_
27-6	4285-4298	preprocessing	_
27-7	4299-4302	and	_
27-8	4303-4314	first-level	_
27-9	4315-4323	modeling	_
27-10	4324-4328	Data	_
27-11	4329-4332	was	_
27-12	4333-4341	acquired	_
27-13	4342-4344	on	_
27-14	4345-4346	a	_
27-15	4347-4354	Philips	_
27-16	4355-4358	1.5	_
27-17	4359-4364	Tesla	_
27-18	4365-4371	Intera	_
27-19	4372-4379	scanner	_
27-20	4380-4383	and	_
27-21	4384-4396	preprocessed	_
27-22	4397-4399	as	_
27-23	4400-4409	described	_
27-24	4410-4419	elsewhere	_
27-25	4420-4423	and	_
27-26	4424-4426	in	_
27-27	4427-4430	the	_
27-28	4431-4441	supplement	_
27-29	4442-4443	.	_

28-1	4444-4451	Briefly	_
28-2	4452-4453	,	_
28-3	4454-4460	images	_
28-4	4461-4465	were	_
28-5	4466-4478	slice-timing	_
28-6	4479-4488	corrected	_
28-7	4489-4490	,	_
28-8	4491-4497	motion	_
28-9	4498-4507	realigned	_
28-10	4508-4509	,	_
28-11	4510-4520	normalized	_
28-12	4521-4523	to	_
28-13	4524-4525	a	_
28-14	4526-4534	standard	_
28-15	4535-4543	template	_
28-16	4544-4545	,	_
28-17	4546-4549	and	_
28-18	4550-4558	smoothed	_
28-19	4559-4560	.	_

29-1	4561-4565	Time	_
29-2	4566-4572	series	_
29-3	4573-4579	values	_
29-4	4580-4584	were	_
29-5	4585-4596	transformed	_
29-6	4597-4599	to	_
29-7	4600-4607	percent	_
29-8	4608-4614	signal	_
29-9	4615-4621	change	_
29-10	4622-4624	on	_
29-11	4625-4626	a	_
29-12	4627-4636	per-voxel	_
29-13	4637-4642	basis	_
29-14	4643-4644	.	_

30-1	4645-4656	First-level	_
30-2	4657-4665	modeling	_
30-3	4666-4674	followed	_
30-4	4675-4680	prior	_
30-5	4681-4685	work	_
30-6	4686-4687	(	_
30-7	4688-4691	see	_
30-8	4692-4702	supplement	_
30-9	4703-4706	and	_
30-10	4707-4708	)	_
30-11	4709-4710	.	_

31-1	4711-4721	Regressors	_
31-2	4722-4724	of	_
31-3	4725-4733	interest	_
31-4	4734-4738	were	_
31-5	4739-4744	those	_
31-6	4745-4755	reflecting	_
31-7	4756-4763	correct	_
31-8	4764-4770	trials	_
31-9	4771-4773	in	_
31-10	4774-4777	the	_
31-11	4778-4785	control	_
31-12	4786-4790	task	_
31-13	4791-4793	or	_
31-14	4794-4798	each	_
31-15	4799-4801	of	_
31-16	4802-4805	the	_
31-17	4806-4811	first	_
31-18	4812-4817	seven	_
31-19	4818-4823	steps	_
31-20	4824-4826	of	_
31-21	4827-4830	the	_
31-22	4831-4834	SOT	_
31-23	4835-4836	,	_
31-24	4837-4844	modeled	_
31-25	4845-4855	separately	_
31-26	4856-4857	.	_

32-1	4858-4862	Step	_
32-2	4863-4868	eight	_
32-3	4869-4872	was	_
32-4	4873-4881	excluded	_
32-5	4882-4885	due	_
32-6	4886-4888	to	_
32-7	4889-4893	poor	_
32-8	4894-4905	performance	_
32-9	4906-4908	by	_
32-10	4909-4917	patients	_
32-11	4918-4919	.	_

33-1	4920-4929	Incorrect	_
33-2	4930-4936	trials	_
33-3	4937-4941	were	_
33-4	4942-4949	modeled	_
33-5	4950-4960	separately	_
33-6	4961-4964	and	_
33-7	4965-4968	are	_
33-8	4969-4972	not	_
33-9	4973-4981	reported	_
33-10	4982-4983	.	_

34-1	4984-4987	Two	_
34-2	4988-4995	primary	_
34-3	4996-5003	outcome	_
34-4	5004-5012	measures	_
34-5	5013-5017	were	_
34-6	5018-5028	calculated	_
34-7	5029-5032	for	_
34-8	5033-5037	each	_
34-9	5038-5045	subject	_
34-10	5046-5047	.	_

35-1	5048-5053	First	_
35-2	5054-5055	,	_
35-3	5056-5059	the	_
35-4	5060-5063	fit	_
35-5	5064-5066	to	_
35-6	5067-5069	an	_
35-7	5070-5079	empirical	_
35-8	5080-5090	inverted-U	_
35-9	5091-5096	shape	_
35-10	5097-5098	(	_
35-11	5099-5107	obtained	_
35-12	5108-5112	from	_
35-13	5113-5115	an	_
35-14	5116-5127	independent	_
35-15	5128-5135	healthy	_
35-16	5136-5142	sample	_
35-17	5143-5144	;	_
35-18	5145-5150	study	_
35-19	5151-5152	1	_
35-20	5153-5155	in	_
35-21	5156-5158	36	_
35-22	5159-5160	)	_
35-23	5161-5164	was	_
35-24	5165-5175	calculated	_
35-25	5176-5178	at	_
35-26	5179-5183	each	_
35-27	5184-5189	voxel	_
35-28	5190-5193	for	_
35-29	5194-5198	each	_
35-30	5199-5210	participant	_
35-31	5211-5212	.	_

36-1	5213-5217	This	_
36-2	5218-5221	fit	_
36-3	5222-5225	was	_
36-4	5226-5234	obtained	_
36-5	5235-5237	by	_
36-6	5238-5248	regressing	_
36-7	5249-5257	observed	_
36-8	5258-5262	task	_
36-9	5263-5273	activation	_
36-10	5274-5276	at	_
36-11	5277-5281	each	_
36-12	5282-5286	step	_
36-13	5287-5289	on	_
36-14	5290-5293	the	_
36-15	5294-5304	inverted-U	_
36-16	5305-5310	shape	_
36-17	5311-5312	,	_
36-18	5313-5317	such	_
36-19	5318-5322	that	_
36-20	5323-5329	larger	_
36-21	5330-5338	positive	_
36-22	5339-5345	values	_
36-23	5346-5354	indicate	_
36-24	5355-5361	better	_
36-25	5362-5365	fit	_
36-26	5366-5367	.	_

37-1	5368-5374	Second	_
37-2	5375-5376	,	_
37-3	5377-5378	a	_
37-4	5379-5383	task	_
37-5	5384-5385	-	_
37-6	5386-5393	control	_
37-7	5394-5402	contrast	_
37-8	5403-5406	was	_
37-9	5407-5417	calculated	_
37-10	5418-5420	as	_
37-11	5421-5424	the	_
37-12	5425-5432	average	_
37-13	5433-5443	activation	_
37-14	5444-5450	across	_
37-15	5451-5454	the	_
37-16	5455-5460	first	_
37-17	5461-5466	seven	_
37-18	5467-5472	steps	_
37-19	5473-5475	of	_
37-20	5476-5479	the	_
37-21	5480-5483	SOT	_
37-22	5484-5489	minus	_
37-23	5490-5500	activation	_
37-24	5501-5503	to	_
37-25	5504-5507	the	_
37-26	5508-5515	control	_
37-27	5516-5520	task	_
37-28	5521-5522	.	_

38-1	5523-5531	Although	_
38-2	5532-5534	we	_
38-3	5535-5538	did	_
38-4	5539-5542	not	_
38-5	5543-5554	hypothesize	_
38-6	5555-5556	a	_
38-7	5557-5570	between-group	_
38-8	5571-5581	difference	_
38-9	5582-5584	in	_
38-10	5585-5589	this	_
38-11	5590-5598	contrast	_
38-12	5599-5600	,	_
38-13	5601-5603	it	_
38-14	5604-5606	is	_
38-15	5607-5608	a	_
38-16	5609-5617	commonly	_
38-17	5618-5622	used	_
38-18	5623-5626	and	_
38-19	5627-5642	straightforward	_
38-20	5643-5650	measure	_
38-21	5651-5653	of	_
38-22	5654-5662	regional	_
38-23	5663-5668	brain	_
38-24	5669-5679	activation	_
38-25	5680-5682	to	_
38-26	5683-5686	the	_
38-27	5687-5690	SOT	_
38-28	5691-5699	relative	_
38-29	5700-5702	to	_
38-30	5703-5706	the	_
38-31	5707-5714	control	_
38-32	5715-5719	task	_
38-33	5720-5721	.	_

39-1	5722-5734	Second-level	_
39-2	5735-5743	modeling	_
39-3	5744-5748	Both	_
39-4	5749-5756	outcome	_
39-5	5757-5765	measures	_
39-6	5766-5767	(	_
39-7	5768-5778	regression	_
39-8	5779-5784	betas	_
39-9	5785-5795	indicating	_
39-10	5796-5799	fit	_
39-11	5800-5802	to	_
39-12	5803-5806	the	_
39-13	5807-5817	inverted-U	_
39-14	5818-5825	pattern	_
39-15	5826-5827	,	_
39-16	5828-5831	and	_
39-17	5832-5840	contrast	_
39-18	5841-5847	values	_
39-19	5848-5851	for	_
39-20	5852-5859	overall	_
39-21	5860-5870	activation	_
39-22	5871-5872	)	_
39-23	5873-5877	were	_
39-24	5878-5886	analyzed	_
39-25	5887-5889	in	_
39-26	5890-5891	a	_
39-27	5892-5898	series	_
39-28	5899-5901	of	_
39-29	5902-5908	robust	_
39-30	5909-5915	models	_
39-31	5916-5917	;	_
39-32	5918-5925	t-tests	_
39-33	5926-5929	for	_
39-34	5930-5935	group	_
39-35	5936-5947	comparisons	_
39-36	5948-5950	or	_
39-37	5951-5959	multiple	_
39-38	5960-5971	regressions	_
39-39	5972-5975	for	_
39-40	5976-5983	testing	_
39-41	5984-5991	effects	_
39-42	5992-5994	of	_
39-43	5995-5997	WM	_
39-44	5998-6006	capacity	_
39-45	6007-6010	and	_
39-46	6011-6016	group	_
39-47	6017-6018	,	_
39-48	6019-6021	as	_
39-49	6022-6033	appropriate	_
39-50	6034-6035	.	_

40-1	6036-6041	These	_
40-2	6042-6048	models	_
40-3	6049-6058	evaluated	_
40-4	6059-6060	1	_
40-5	6061-6062	)	_
40-6	6063-6070	whether	_
40-7	6071-6076	there	_
40-8	6077-6081	were	_
40-9	6082-6087	group	_
40-10	6088-6099	differences	_
40-11	6100-6102	in	_
40-12	6103-6113	activation	_
40-13	6114-6116	or	_
40-14	6117-6127	inverted-U	_
40-15	6128-6131	fit	_
40-16	6132-6133	,	_
40-17	6134-6137	and	_
40-18	6138-6139	2	_
40-19	6140-6141	)	_
40-20	6142-6149	whether	_
40-21	6150-6160	activation	_
40-22	6161-6163	or	_
40-23	6164-6174	inverted-U	_
40-24	6175-6178	fit	_
40-25	6179-6186	related	_
40-26	6187-6189	to	_
40-27	6190-6192	WM	_
40-28	6193-6201	capacity	_
40-29	6202-6204	in	_
40-30	6205-6209	each	_
40-31	6210-6215	group	_
40-32	6216-6217	,	_
40-33	6218-6221	and	_
40-34	6222-6229	whether	_
40-35	6230-6235	there	_
40-36	6236-6240	were	_
40-37	6241-6246	group	_
40-38	6247-6258	differences	_
40-39	6259-6261	in	_
40-40	6262-6266	this	_
40-41	6267-6279	relationship	_
40-42	6280-6281	(	_
40-43	6282-6287	group	_
40-44	6288-6290	by	_
40-45	6291-6293	WM	_
40-46	6294-6302	capacity	_
40-47	6303-6314	interaction	_
40-48	6315-6316	)	_
40-49	6317-6318	.	_

41-1	6319-6322	See	_
41-2	6323-6333	supplement	_
41-3	6334-6337	for	_
41-4	6338-6346	multiple	_
41-5	6347-6357	comparison	_
41-6	6358-6369	corrections	_
41-7	6370-6371	.	_

42-1	6372-6378	Region	_
42-2	6379-6381	of	_
42-3	6382-6390	Interest	_
42-4	6391-6403	Second-level	_
42-5	6404-6412	analyses	_
42-6	6413-6417	were	_
42-7	6418-6423	first	_
42-8	6424-6431	carried	_
42-9	6432-6435	out	_
42-10	6436-6438	in	_
42-11	6439-6441	an	_
42-12	6442-6455	anatomically-	_
42-13	6456-6459	and	_
42-14	6460-6480	functionally-defined	_
42-15	6481-6482	a	_
42-16	6483-6489	priori	_
42-17	6490-6496	region	_
42-18	6497-6499	of	_
42-19	6500-6508	interest	_
42-20	6509-6510	(	_
42-21	6511-6514	ROI	_
42-22	6515-6516	)	_
42-23	6517-6519	of	_
42-24	6520-6529	bilateral	_
42-25	6530-6535	DLPFC	_
42-26	6536-6537	(	_
42-27	6538-6541	see	_
42-28	6542-6552	supplement	_
42-29	6553-6554	)	_
42-30	6555-6556	,	_
42-31	6557-6560	and	_
42-32	6561-6573	subsequently	_
42-33	6574-6576	in	_
42-34	6577-6579	an	_
42-35	6580-6591	exploratory	_
42-36	6592-6603	whole-brain	_
42-37	6604-6612	analysis	_
42-38	6613-6614	.	_

